Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoATP: Neoadjuvant Pyrotinib + Trastuzumab + Chemo in HER2+ Breast Cancer
NCT04126525Phase 2Active, not recruiting
- Sponsor
- Renji Hospital
- Start
- Jun 2019
- Primary completion
- Oct 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Renji Hospital. Primary endpoint: Pathological Complete Response. Started Jun 2019; status: active, not recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04126525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126525.